PATENT & TECHNOLOGY LICENSE AGREEMENT AGT. NO. L2549-LogicBioPatent and Technology License Agreement • August 13th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Texas
Contract Type FiledAugust 13th, 2018 Company Industry JurisdictionThis Patent and Technology License Agreement (“Agreement”) is between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 201 West 7th Street, Austin, Texas 78701 on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094 (“Licensor”) and LogicBio Therapeutics, Inc., a Delaware corporation, with its principal place of business at 700 Main Street, Cambridge, MA 02139 (“Licensee”) (collectively, “Parties”, or singly, “Party”).
AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • August 13th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledAugust 13th, 2018 Company Industry JurisdictionThis Amended and Restated Exclusive (Equity) Agreement (“Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and LogicBio Therapeutics, Inc. (“LogicBio”), a corporation having a principal place of business at 700 Main Street, Cambridge, MA 02139, is effective on the 31st day of January, 2018 (“Amendment Date”).
LOGICBIO THERAPEUTICS, INC. CONSULTING AGREEMENTConsulting Agreement • August 13th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledAugust 13th, 2018 Company Industry JurisdictionThis Consulting Agreement (this “Agreement”) is made and entered into as of April 1, 2018 (the “Effective Date”) by and between LogicBio Therapeutics, Inc., a Delaware corporation with its principal place of business at c/o LabCentral, 700 North Main Street, Cambridge, MA 02139 (the “Company”), and Mark A. Kay, MD, PhD, an individual with his/her principal place of business at 1071 Peninsular CT ., Los Altos CA 94024 (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).